Time Is Money: Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?
Executive Summary
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.
You may also be interested in...
Distortion And Inflation In Measuring Pharma M&A
Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.
Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Stockwatch: Some Failed Drugs Never Die, They Just Find New Investors
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Need a specific report? 1000+ reports available
Buy Reports